Vascular Protection of ACE Inhibitors

In their enthusiastic review on the renin-angiotensin system and atherothrombotic disease,¹ Jacoby and Rader state that

. . . the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) found that angiotensin-converting enzyme (ACE) inhibition in 6105 patients with a history of cardiovascular accidents or transient ischemic attacks reduced the secondary outcome of cardiac death or acute MI. . . .